-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Akebia Therapeutics (NASDAQ:AKBA) Now Covered by Analysts at StockNews.com
Akebia Therapeutics (NASDAQ:AKBA) Now Covered by Analysts at StockNews.com
Analysts at StockNews.com assumed coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report issued on Tuesday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Akebia Therapeutics Stock Down 5.4 %
Akebia Therapeutics stock opened at $0.36 on Tuesday. Akebia Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.35. The firm has a market capitalization of $67.09 million, a price-to-earnings ratio of -0.39 and a beta of 1.50. The firm's fifty day moving average price is $0.40 and its two-hundred day moving average price is $0.68. The company has a current ratio of 1.30, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.
Get Akebia Therapeutics alerts:Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.54. The company had revenue of $126.76 million during the quarter, compared to the consensus estimate of $49.10 million. Akebia Therapeutics had a negative net margin of 55.04% and a negative return on equity of 197.12%. During the same quarter in the prior year, the company posted ($0.51) earnings per share. On average, equities research analysts predict that Akebia Therapeutics will post -0.44 earnings per share for the current fiscal year.
Institutional Trading of Akebia Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in AKBA. Dimensional Fund Advisors LP raised its holdings in shares of Akebia Therapeutics by 23.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,593,841 shares of the biopharmaceutical company's stock valued at $5,862,000 after purchasing an additional 498,078 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Akebia Therapeutics by 37.2% in the fourth quarter. Teacher Retirement System of Texas now owns 32,286 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 8,759 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in Akebia Therapeutics during the fourth quarter worth about $30,000. Virtus ETF Advisers LLC increased its holdings in Akebia Therapeutics by 18.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 69,015 shares of the biopharmaceutical company's stock worth $156,000 after buying an additional 10,772 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in Akebia Therapeutics during the first quarter worth about $75,000. Hedge funds and other institutional investors own 31.56% of the company's stock.Akebia Therapeutics Company Profile
(Get Rating)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
Featured Articles
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Analysts at StockNews.com assumed coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report issued on Tuesday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
斯托克新聞網的分析師在週二發佈的一份研究報告中假設了木通治療公司(納斯達克代碼：AKBA-GET評級)的股票。該經紀公司對這家生物製藥公司的股票設定了“持有”評級。
Akebia Therapeutics Stock Down 5.4 %
木通治療類股下跌5.4%
Akebia Therapeutics stock opened at $0.36 on Tuesday. Akebia Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.35. The firm has a market capitalization of $67.09 million, a price-to-earnings ratio of -0.39 and a beta of 1.50. The firm's fifty day moving average price is $0.40 and its two-hundred day moving average price is $0.68. The company has a current ratio of 1.30, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.
木通治療公司的股票週二開盤報0.36美元。木通治療公司的一年低點為0.30美元，一年高位為3.35美元。該公司市值為6709萬美元，市盈率為-0.39倍，貝塔係數為1.50。該公司的50日移動均線價格為0.40美元，200日移動均線價格為0.68美元。該公司的流動比率為1.30，速動比率為1.15，債務權益比率為0.51。
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.54. The company had revenue of $126.76 million during the quarter, compared to the consensus estimate of $49.10 million. Akebia Therapeutics had a negative net margin of 55.04% and a negative return on equity of 197.12%. During the same quarter in the prior year, the company posted ($0.51) earnings per share. On average, equities research analysts predict that Akebia Therapeutics will post -0.44 earnings per share for the current fiscal year.
木通治療公司(納斯達克代碼：AKBA-GET評級)最近一次公佈收益結果是在8月4日星期四。這家生物製藥公司公佈本季度每股收益為0.23美元，比普遍預期的每股收益(0.31美元)高出0.54美元。該公司本季度營收為1.2676億美元，而市場普遍預期為4910萬美元。木通治療公司的淨利潤率為負55.04%，淨資產回報率為負197.12%。去年同期，該公司公佈的每股收益為0.51美元。平均而言，股票研究分析師預測，木通治療公司本財年的每股收益將為0.44美元。
Institutional Trading of Akebia Therapeutics
木通治療的制度性交易
Akebia Therapeutics Company Profile
木通治療公司簡介
(Get Rating)
(獲取評級)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
木通治療公司是一家生物製藥公司，專注於腎臟疾病患者治療藥物的開發和商業化。該公司的主要研究產品候選產品是vadustat，這是一種口服療法，正處於第三階段開發，用於治療依賴透析和非透析依賴的成年患者的慢性腎臟疾病(CKD)引起的貧血。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免費獲取StockNews.com關於木通治療的研究報告(AKBA)
- 甲骨文的短期痛苦可能是你的長期收益
- Lucid看起來像是電動汽車的贏家
- 仍然愛着它：投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎？
- 自動區重新進入拉力賽模式，新高在望
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受木通治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對木通治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧